A new non-invasive blood test can identify thousands of genetic conditions in a fetus by analyzing DNA fragments in the mother’s bloodstream, potentially replacing invasive procedures like amniocentesis. Developed by researchers at the Broad Institute of MIT and Harvard, the test—known as non-invasive fetal sequencing (NIFS)—demonstrated a 95-99% accuracy rate in identifying genetic variants during a validation study of 565 pregnancies.
How Does Non-Invasive Fetal Sequencing Work?
The NIFS technique functions by isolating tiny fragments of fetal DNA that naturally circulate within the mother’s blood during pregnancy. According to Dr. Christopher Whelan, a senior computational scientist at the Broad Institute, the test uses advanced sequencing to screen across nearly 23,000 genes. This allows clinicians to identify markers for rare disorders such as Noonan syndrome, Charge syndrome, and achondroplasia, which were previously difficult to detect without physical sampling of the amniotic fluid.
Why This Test May Replace Amniocentesis
Current diagnostic standards, such as amniocentesis and chorionic villus sampling (CVS), carry a physical risk to the pregnancy. Dr. Whelan notes that amniocentesis, which involves inserting a needle into the uterus to collect fluid, results in a miscarriage in approximately one in every 200 cases. By providing a safer alternative, NIFS aims to reduce the stress and medical risks associated with traditional prenatal testing while maintaining high diagnostic accuracy.
Current prenatal blood tests are typically limited to screening for a few conditions, such as Down’s syndrome. The NIFS technique expands this capability to include the majority of conditions listed on the Genomics England fetal anomalies panel—a catalog of over 2,500 genes.
What Are the Clinical Risks of Expanded Screening?
While the technical achievement is significant, some experts urge caution regarding how the data is used. Prof. Angus Clarke of Cardiff University warns that exploratory screening could identify genes of unknown significance. According to Prof. Clarke, providing parents with potential answers for conditions that are not yet understood or treatable may lead to unnecessary medical surveillance and significant emotional distress. He emphasizes that the test is most valuable when used to confirm a suspected condition where prenatal intervention is possible.
How Do These Methods Compare?
| Feature | Invasive (Amniocentesis) | Non-Invasive (NIFS) |
|---|---|---|
| Method | Needle collection of fluid | Maternal blood draw |
| Miscarriage Risk | Approx. 1 in 200 | None |
| Accuracy | Very High | 95-99% of variants |
Frequently Asked Questions
Is this test currently available to the public?
The test was presented to the European Society for Human Genetics and remains in the validation stage. While the results are promising, it is not yet a standard clinical offering.
At what stage of pregnancy can this test be performed?
In the validation study of 565 pregnancies, the researchers tested samples at an average of 17 weeks gestation.
Does this replace the need for ultrasound scans?
No. Dr. Whelan suggests this test is designed as a “frontline” tool for cases where an ultrasound or other initial screening has already identified a potential anomaly.
Have questions about how genomic medicine is changing prenatal care? Share your thoughts in the comments below or subscribe to our health technology newsletter for the latest updates in medical research.
Worth a look